The biotechnology company EquiCord-YMAS has submitted to the European Medicines Agency (EMA) the marketing authorization for the first veterinary medicine based on umbilical cord stem cells. A milestone that positions the Spanish biotech as an international leader in animal regenerative medicine.
Their studies focused on regenerative medicine, the result of more than 5 years of research, have demonstrated the effectiveness of using stem cells for the treatment of joint injuries in high-performance horses.
The medicine is indicated for the treatment of joint injuries in equines but paves the way for other future applications in cell therapy.
View news on INnovadores by El Mundo